Comment: As Big Pharma deals return, so will divestments to placate regulators
Big Pharma deals are back, and they will surely involve overlaps that will need to be resolved with asset sales to appease competition enforcers. But past EU reviews show that fixes...To view the full article, register now.
Already a subscriber? Click here to view full article